Cytokine landscape in hospitalized children with multisystem inflammatory syndrome

Sci Rep. 2024 Oct 1;14(1):22803. doi: 10.1038/s41598-024-73956-x.

Abstract

The etiology of multisystem inflammatory syndrome in children (MIS-C), frequently observed following COVID-19 infection, remains elusive. This study unveils insights derived from cytokine analysis in the sera of MIS-C patients, both before and after the administration of intravenous immunoglobulin (IVIG) and glucocorticosteroids (GCS). In this study, we employed a comprehensive 45-cytokine profile encompassing a spectrum of widely recognized proinflammatory and antiinflammatory cytokines, as well as growth factors, along with other soluble mediators. The analysis delineates three principal cytokine-concentration patterns evident in the patients' sera. Pattern no.1 predominantly features proinflammatory cytokines (IL-6, IL-15, IL-1ra, granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor α (TNFα), C-X-C motif chemokine ligand 10 (CXCL10/ IP-10), and IL-10) exhibiting elevated concentrations upon admission, swiftly normalizing post-hospital treatment. Pattern no. 2 includes cytokines (IL-17 A, IL-33, IFNγ, vascular endothelial growth factor (VEGF), and programmed death ligand (PD-L1)) with moderately elevated levels at admission, persisting over 7-10 days of hospitalization despite the treatment. Pattern no. 3 comprises cytokines which concentrations escalated after 7-10 days of hospitalization and therapy, including IL-1α, IL-1β, IL-2, IL-13, platelet-derived growth factor AA/BB (PDGF AA/BB). The observed in cytokine profile of MIS-C patients showed a transition from acute inflammation to sustaining inflammation which turned into induction of humoral memory mechanisms and various defense mechanisms, contributing to recovery.

Keywords: COVID-19; Cytokines; Intravenous immunoglobulins (IVIG); Multisystem inflammatory syndrome in children (MIS-C).

MeSH terms

  • Adolescent
  • COVID-19* / blood
  • COVID-19* / complications
  • COVID-19* / immunology
  • Child
  • Child, Hospitalized
  • Child, Preschool
  • Cytokines* / blood
  • Female
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Infant
  • Male
  • SARS-CoV-2 / immunology
  • Systemic Inflammatory Response Syndrome* / blood
  • Systemic Inflammatory Response Syndrome* / immunology

Substances

  • Cytokines
  • Immunoglobulins, Intravenous
  • Glucocorticoids

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related